Charles River Laboratories International, Inc. Share Price Mexican S.E.
Equities
CRL *
US1598641074
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4,049 MXN | +1.84% | -.--% | +3.57% |
Sales 2024 * | 4.22B 74.6B 329B | Sales 2025 * | 4.53B 80.05B 353B | Capitalization | 10.71B 189B 836B |
---|---|---|---|---|---|
Net income 2024 * | 406M 7.18B 31.69B | Net income 2025 * | 513M 9.07B 40.04B | EV / Sales 2024 * | 3 x |
Net Debt 2024 * | 1.94B 34.37B 152B | Net Debt 2025 * | 1.46B 25.76B 114B | EV / Sales 2025 * | 2.69 x |
P/E ratio 2024 * |
26.3
x | P/E ratio 2025 * |
21.3
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.94% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | +1.84% | ||
3 months | +3.57% | ||
6 months | +16.73% | ||
Current year | +3.57% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 31/12/75 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 24/04/22 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 31/03/89 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 31/12/02 |
Virginia Wilson
BRD | Director/Board Member | 68 | 30/09/19 |
Robert Bertolini
BRD | Director/Board Member | 61 | 24/01/11 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- CRL Stock
- CRL * Stock